Lonza and Sheba Medical Centre Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy

Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform • The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care • Three patients had complete responses, with another patient still under evaluation • Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform • The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care • Three patients had complete responses, with another patient still under evaluation …

Read the source article at TextileFuture – by Virginia
2021-08-13 08:10:48